Clinical results support strong safety and tolerability for BXQ-350.
Topline results support progression into Phase II studies.
FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019
Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature a clinical poster presentation at the National Organization for Rare Disorders’ (NORD) Rare Disease and Orphan Products Breakthrough Summit taking place October 21-22, 2019 in Washington, D.C. at the Marriott Wardman Park.
NORD Annual Meeting
The NORD Annual Meeting brings together approximately 1000 multi-stakeholders in the rare disease community including Senior FDA officials, advocacy/patient groups, bio/pharma and solution services professionals.
Bexion’s poster is entitled, “First-in-human, First-in-class Phase 1 Study of BXQ-350 for Solid Tumors and Gliomas,” and includes updated clinical information from the original poster presented at the American Society of Clinical Oncology (ASCO) in June, 2018.
Strong Safety and Tolerability
“This Phase 1 study of BXQ-350 demonstrated a strong safety and tolerability profile for a first-in-class, novel approach to treating brain and solid tumors,” said Ray Takigiku, CEO and President of Bexion. “We are also highly encouraged by the evidence of possible clinical activity in some of our patients and are excited to explore the potential of this compound in future clinical trials.”
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases. Bexion has completed multi-site first-in-human Phase 1 clinical study of BXQ-350 for solid tumors and gliomas. A similar pediatric Phase 1 trial is currently underway.
Margaret van Gilse
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Bexion has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Bexion’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements. Bexion undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.